Limits...
MRI characterization of uterine fibroids may predict success of GnRH agonist therapy prior to magnetic resonance focused ultrasound (MRgFUS) treatment

View Article: PubMed Central - HTML

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

In managing women with large uterine fibroids, GnRH agonists can be used to reduce fibroid volume and decrease vascularity to enhance treatment outcomes with MRgFUS... The purpose of this study was to examine the responsiveness of fibroids to pre-treatment with a GnRH agonist in relation to their appearance on T2 weighted images and MRgFUS treatment outcomes... Fifteen women (ages 34-52) with symptomatic uterine fibroids were pre-treated with a GnRH agonist prior to undergoing MRgFUS treatment using the ExAblate device. 7 patients received treatment for 3 months, 4 received treatment for 4 months, 2 received treatment for 6 months and 2 received treatment for an unknown time before the MRgFUS procedure... Other than the 2 patients with unknown GnRH agonist therapy times, all patients obtained their last GnRH agonist injection 3-4 weeks before MRgFUS treatment... A total of 22 fibroids were treated with MRgFUS: 17 hypointense, 3 heterogeneously hypointense, 1 heterogeneously hyperintense and 1 isointense fibroid... The average Joules of energy delivered per sonication was greater for isointense (4550 J) and heterogeneously hyperintense (4200 J) fibroids than for heterogeneously hypointense (3227 J) and hypointense (2654 J) fibroids... Additionally, the volume of tissue ablation per Joule of energy applied was significantly larger for the heterogeneously hypointense (0.066 cm3) and heterogeneously hyperintense (0.057 cm3) than for the hypointense (0.036 cm3) and isointense (0.018 cm3)... The NPV per fibroid was greater for heterogeneously hyperintense (85%), heterogeneously hypointense (63%) and hypointense (72%) fibroids than for isointense (32%) fibroids... Fibroid image characteristics may be used to predict the effectiveness of GnRH agonist therapy prior to MRgFUS treatment... While more vascular fibroids require greater energy to treat, they show a more favorable response to pre-treatment with a GnRH agonist in terms of fibroid volume reduction and thermoablative treatment effectiveness than hypointense fibroids.

No MeSH data available.


Related in: MedlinePlus

Sagittal T2-weighted image depicting a 471 cc heterogeneously hyperintense fibroid.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4489603&req=5

Figure 1: Sagittal T2-weighted image depicting a 471 cc heterogeneously hyperintense fibroid.


MRI characterization of uterine fibroids may predict success of GnRH agonist therapy prior to magnetic resonance focused ultrasound (MRgFUS) treatment
Sagittal T2-weighted image depicting a 471 cc heterogeneously hyperintense fibroid.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4489603&req=5

Figure 1: Sagittal T2-weighted image depicting a 471 cc heterogeneously hyperintense fibroid.

View Article: PubMed Central - HTML

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

In managing women with large uterine fibroids, GnRH agonists can be used to reduce fibroid volume and decrease vascularity to enhance treatment outcomes with MRgFUS... The purpose of this study was to examine the responsiveness of fibroids to pre-treatment with a GnRH agonist in relation to their appearance on T2 weighted images and MRgFUS treatment outcomes... Fifteen women (ages 34-52) with symptomatic uterine fibroids were pre-treated with a GnRH agonist prior to undergoing MRgFUS treatment using the ExAblate device. 7 patients received treatment for 3 months, 4 received treatment for 4 months, 2 received treatment for 6 months and 2 received treatment for an unknown time before the MRgFUS procedure... Other than the 2 patients with unknown GnRH agonist therapy times, all patients obtained their last GnRH agonist injection 3-4 weeks before MRgFUS treatment... A total of 22 fibroids were treated with MRgFUS: 17 hypointense, 3 heterogeneously hypointense, 1 heterogeneously hyperintense and 1 isointense fibroid... The average Joules of energy delivered per sonication was greater for isointense (4550 J) and heterogeneously hyperintense (4200 J) fibroids than for heterogeneously hypointense (3227 J) and hypointense (2654 J) fibroids... Additionally, the volume of tissue ablation per Joule of energy applied was significantly larger for the heterogeneously hypointense (0.066 cm3) and heterogeneously hyperintense (0.057 cm3) than for the hypointense (0.036 cm3) and isointense (0.018 cm3)... The NPV per fibroid was greater for heterogeneously hyperintense (85%), heterogeneously hypointense (63%) and hypointense (72%) fibroids than for isointense (32%) fibroids... Fibroid image characteristics may be used to predict the effectiveness of GnRH agonist therapy prior to MRgFUS treatment... While more vascular fibroids require greater energy to treat, they show a more favorable response to pre-treatment with a GnRH agonist in terms of fibroid volume reduction and thermoablative treatment effectiveness than hypointense fibroids.

No MeSH data available.


Related in: MedlinePlus